{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:06:40Z","timestamp":1791443200312,"version":"4.3.3"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Psoriatic arthritis (PsA) is a chronic inflammatory disease that significantly impacts patients\u2019 quality of life, underscoring the importance of timely diagnosis and appropriate treatment. In Colombia, the estimated prevalence is 13.5 cases per100,000 inhabitants; however, few studies have addressed this condition in the local context. Although there is no single international consensus on treatment, various clinical guidelines agree on the effectiveness of biologic therapies. Despite this, data on Colombian patients treated with biologic agents remain scarce. Therefore, this study aims to describe the clinical and paraclinical characteristics, as well as the outcomes, of patients with PsA receiving biologic treatments\u2014representing the first such analysis conducted in our country.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective descriptive study was conducted using medical records of patients with PsA treated with biologic therapies at a high-complexity hospital in Colombia between 2011 and 2021.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 127 patients were included, 55.1% of whom were women, with a mean age of 50.3\u00a0years. Hypertension was the most common comorbidity, and peripheral arthritis was the most frequent subtype (55.7%). TNF inhibitors were the most commonly used biologics, followed by IL-17 and IL-12\/23 inhibitors, with greater persistence observed with secukinumab and adalimumab. A total of 39.4% of patients switched biologics, most commonly to secukinumab. Only 5.5% discontinued treatment, primarily due to infections. The median time in biological therapy was 36.5\u00a0months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Few studies described PsA patients treated with biologics in Latin America, making these findings a valuable contribution on biologic usage and persistence patterns in Colombia, with a high persistence population. The results highlight the heterogeneity of this disease and the need for personalized, continuous management guided by specialists.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1559168","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:13:13Z","timestamp":1756451593000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["High persistence of biologic therapy in patients with Psoriatic arthritis: a real-world evidence from a high-complexity hospital in Colombia"],"prefix":"10.3389","volume":"16","author":[{"given":"Andr\u00e9s","family":"Hormaza-Jaramillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leidy Johanna","family":"Hurtado-Bermudez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Pe\u00f1aloza Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Delgado-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.reuma.2018.11.007","article-title":"Patrones de tratamiento biol\u00f3gico en pacientes con enfermedades articulares inflamatorias. Estudio retrospectivo de 4 a\u00f1os de seguimiento","volume":"16","author":"Ca\u00f1ete","year":"2020","journal-title":"Reumatol. Cl\u00ednica"},{"key":"B2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1756-185X.2010.01540.x","article-title":"Psoriatic arthritis: a systematic review","volume":"13","author":"Cantini","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"T583","DOI":"10.1016\/j.ad.2022.01.040","article-title":"[translated article] practical update of the guidelines published by the psoriasis group of the Spanish academy of dermatology and venereology (GPs) on the treatment of psoriasis with biologic agents: part 2-Management of special populations, patients with comorbid conditions, and risk","volume":"113","author":"Carrascosa","year":"2022","journal-title":"Actas Dermosifiliogr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/rheumatology\/keae172","article-title":"Enhancing current guidance for psoriatic arthritis and its comorbidities: recommendations from an expert consensus panel","volume":"64","author":"Coates","year":"2025","journal-title":"Rheumatology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","article-title":"Medication compliance and persistence: terminology and definitions","volume":"11","author":"Cramer","year":"2008","journal-title":"Value Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/OARRR.S56073","article-title":"Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders","volume":"9","author":"D\u2019Angelo","year":"2017","journal-title":"Open Access Rheumatol. Res. Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s11926-018-0746-0","article-title":"Novel therapeutics in psoriatic arthritis. What is in the pipeline?","volume":"20","author":"Elalouf","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1016\/j.rcreue.2023.02.007","article-title":"Clinical practice guideline for the treatment of psoriatic arthritis in Colombia","volume":"30","author":"Fern\u00e1ndez-\u00c1vila","year":"","journal-title":"Rev. Colomb. Reumatol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.rcreu.2022.08.001","article-title":"Prevalence and demographic characteristics of psoriatic arthritis in Colombia: data from the national health registry 2012\u20132018","volume":"30","author":"Fern\u00e1ndez-\u00c1vila","year":"","journal-title":"Rev. Colomb. Reumatol."},{"key":"B11","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.reuma.2019.04.006","article-title":"Caracter\u00edsticas epidemiol\u00f3gicas y eventos adversos de los pacientes con artritis psori\u00e1sica en tratamiento con terapias biol\u00f3gicas en Galicia","volume":"17","author":"Garc\u00eda Porr\u00faa","year":"2021","journal-title":"Reumatol. Cl\u00ednica"},{"key":"B12","doi-asserted-by":"publisher","first-page":"rkaa070","DOI":"10.1093\/rap\/rkaa070","article-title":"Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden","volume":"4","author":"Geale","year":"2020","journal-title":"Rheumatol. Adv. Pract."},{"key":"B13","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","article-title":"Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review","volume":"21","author":"Kamata","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00296-022-05126-z","article-title":"Patient characteristics, treatment patterns and disease outcomes in patients with psoriatic arthritis followed in a combined dermatology\u2013rheumatology clinic: a retrospective real-world study","volume":"42","author":"Klavdianou","year":"2022","journal-title":"Rheumatol. Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis-a systematic review and meta-analysis","volume":"63","author":"Lembke","year":"2024","journal-title":"Rheumatol. Oxf."},{"key":"B17","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.adengl.2013.10.013","article-title":"Psoriatic arthritis: an update","volume":"105","author":"L\u00f3pez-Ferrer","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"B18","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.reuma.2021.05.005","article-title":"Artritis psori\u00e1sica: interacci\u00f3n entre enfermedades cardiometab\u00f3licas y la actividad inflamatoria de la enfermedad","volume":"18","author":"Lorenzo Mart\u00edn","year":"2022","journal-title":"Reumatol. Cl\u00ednica"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000638","DOI":"10.1136\/rmdopen-2017-000638","article-title":"Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the corrona psoriatic arthritis\/spondyloarthritis registry","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"B20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"B21","doi-asserted-by":"publisher","first-page":"i37","DOI":"10.1093\/rheumatology\/kez383","article-title":"Treatment guidelines in psoriatic arthritis","volume":"59","author":"Ogdie","year":"2020","journal-title":"Rheumatol. Oxf. Engl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s40744-022-00440-1","article-title":"Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population","volume":"9","author":"Perrone","year":"2022","journal-title":"Rheumatol. Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","article-title":"Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French health insurance database","volume":"158","author":"Pina Vegas","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B24","unstructured":"RESOLUCI\u00d3N 2024001339 DEL 15 DE ENERO DE 2024\n          \n          \n          2024"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e001117","DOI":"10.1136\/rmdopen-2019-001117","article-title":"Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis","volume":"6","author":"Ruyssen-Witrand","year":"2020","journal-title":"RMD Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1007\/s40744-023-00588-4","article-title":"Identification of the minimal disease activity domains achieved based on different treatments in psoriatic arthritis","volume":"10","author":"Scriffignano","year":"2023","journal-title":"Rheumatol. Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"CD008794","DOI":"10.1002\/14651858.CD008794.pub2","article-title":"Adverse effects of biologics: a network meta\u2010analysis and cochrane overview","volume":"2011","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American college of rheumatology\/national psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","author":"Veale","year":"2025"},{"key":"B30","unstructured":"Long-term persistence of first-line biologics for psoriasis and psoriatic arthritis\n          \n          \n            \n              Vegas\n              L. P.\n            \n            \n              Penso\n              L.\n            \n            \n              Claudepierre\n              P.\n            \n            \n              Sbidian\n              E.\n            \n          \n          \n          2025"},{"key":"B31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.18553\/jmcp.2018.24.7.623","article-title":"Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database","volume":"24","author":"Walsh","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1559168\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T07:13:15Z","timestamp":1756451595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1559168\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1559168"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1559168","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1559168"}}